Home > Insider Trading > Filing (0000899243-17-029263)

Filing Details

Accession Number:: 0000899243-17-029263
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-12-19 20:44:06
Reporting Period:: 2017-12-15

Accepted Time:: 2017-12-19 20:44:06
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1484565	Soleno Therapeutics Inc	SLNO	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1398936	Vivo Ventures V Affiliates Fund, L.p.	505 Hamilton Avenue, Suite 207 Palo Alto CA 94301	No	No	Yes	No
1398937	Vivo Ventures Fund V, L.p.	505 Hamilton Avenue, Suite 207 Palo Alto CA 94301	No	No	Yes	No
1399028	Vivo Ventures V, Llc	505 Hamilton Avenue, Suite 207 Palo Alto CA 94301	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-12-15	1,072,888	$1.84	3,888,137	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2017-12-15	12,592	$1.84	45,667	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Stock Warrant (Right to Buy)	Acquisiton	2017-12-15	793,937	$0.00	793,937	$2.00
Common Stock	Common Stock Warrant (Right to Buy)	Acquisiton	2017-12-15	9,318	$0.00	9,318	$2.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
793,937	2017-12-15		No	4	P	Indirect
9,318	2017-12-15		No	4	P	Indirect

Footnotes

The securities are held directly by Vivo Ventures Fund V. L.P. ("Vivo Ventures Fund V"). The Reporting Person is the sole general partner of Vivo Ventures Fund V, and may be deemed to beneficially own such securities. The Reporting Person holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. Edgar Engleman, Albert Cha and Frank Kung are members of the Reporting Person and disclaim beneficial ownership of the securities held by Vivo Ventures Fund V, except to the extent of any pecuniary interest therein.
The securities are held directly by Vivo Ventures V Affiliates Fund L.P. ("Vivo Ventures V Affiliates Fund"). The Reporting Person is the sole general partner of Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such securities. The Reporting Person holds voting and dispositive power with respect to the securities held by Vivo Ventures V Affiliates Fund. Edgar Engleman, Albert Cha and Frank Kung are members of the Reporting Person and disclaim beneficial ownership of the securities held by Vivo Ventures V Affiliates Fund, except to the extent of any pecuniary interest therein.
The warrant has a term of three years and, in the event of positive Phase III results for Diazoxide Choline Controlled-Release (DCCR) tablet in Prader-Willi syndrome (PWS), the warrant will expire 30 days from the announcement of such results.
The reported securities are included within 1,072,888 units purchased by the Reporting Person for $1.8425 per unit. Each unit consists of one share of common stock and one warrant to acquire 74% of a share of common stock.
The reported securities are included within 12,592 units purchased by the Reporting Person for $1.8425 per unit. Each unit consists of one share of common stock and one warrant to acquire 74% of a share of common stock.